Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Größe/SKU | Verfügbarkeit | Preis |
|---|
Über diesen Artikel
Empirische Formel (Hill-System):
C29H27F3N6O · xHCl
Molekulargewicht:
532.56 (free base basis)
UNSPSC Code:
12352200
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenQuality Segment
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
-10 to -25°C
Biochem/physiol Actions
AP24534 (Ponatinib) is a reversible, ATP-competitive, BBB-permeable and orally active pan-BCR-ABL inhibitor engineered to overcome multidrug-resistant CML. Its design features a rigid ethynyl linker that bypasses the steric hindrance of the T315I "gatekeeper" mutation, yielding profound potency against native ABL (IC50 0.37 nM), T315I (IC50 2.0 nM), and T315I-inclusive compound mutants (IC50 0.30–0.44 nM). This efficacy extends to cellular models, where it suppresses CrkL phosphorylation and inhibits proliferation in native (IC50 0.5 nM) and T315I-expressing (IC50 11 nM) cells. Beyond ABL, Ponatinib acts as a multi-kinase inhibitor modulating angiogenesis and stromal signaling, with high affinity for LYN (0.24 nM), PDGFRα (1.1 nM), VEGFR2 (1.5 nM), FGFR1-4 (~2.2 nM), SRC (5.4 nM), KIT (~12.5 nM), and FLT3 (~13 nM). Mechanistically, it halts STAT5, ERK, and AKT signaling to trigger cell cycle arrest and intrinsic apoptosis—driven by caspase-3 cleavage and Bcl-xL/Mcl-1 downregulation—or RIPK1/3-mediated necroptosis. To deepen molecular response against complex resistance, Ponatinib demonstrates significant synergy with MDM2 inhibitors, the allosteric inhibitor asciminib, and the BCL-2 inhibitor venetoclax.
Disclaimer
Hygroscopic, Store with desiccant
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| description ≥98% (HPLC) | description ≥98% (HPLC) | description United States Pharmacopeia (USP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard |
| assay ≥98% (HPLC) | assay ≥98% (HPLC) | assay - | assay - |
| form powder | form powder | form - | form - |
| Quality Level 100 | Quality Level 100 | Quality Level - | Quality Level - |
| storage temp. -10 to -25°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-30°C |
| solubility DMSO: 2 mg/mL, clear (warmed) | solubility DMSO: 2 mg/mL, clear | solubility - | solubility - |
| storage condition desiccated | storage condition desiccated | storage condition - | storage condition - |
Hazard Classifications
Acute Tox. 3 Oral - Repr. 2 - STOT RE 1 Dermal
Zielorgane
Liver,Bone marrow,Pancreas,Cardio-vascular system
Lagerklasse
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Signalwort
Danger
Gefahrencodes
Sicherheitshinweise
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.



